Janus Capital Group Inc (JNS) Drops 5.67% on January 13

Equities Staff  |

Janus Capital Group Inc (JNS) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 5.67% to $12.23, a loss of $-0.735 per share. Starting at an opening price of $12.81 a share, the stock traded between $12.14 and $12.91 over the course of the trading day. Volume was 5.45 million shares over 26,682 trades, against an average daily volume of 2.47 million shares and a total float of 184.75 million.

The losses send Janus Capital Group Inc down to a market cap of $2.26 billion. In the last year, Janus Capital Group Inc has traded between $18.98 and $12.30, and its 50-day SMA is currently $14.70 and 200-day SMA is $15.89.

The stock has a P/E Ratio of 16.2.

Janus Capital Group Inc and its subsidiaries provide investment management, administration, distribution and related services to individual and institutional investors through mutual funds, separate accounts and subadvised relationships.

Janus Capital Group Inc is based out of Denver, CO and has some 1,209 employees. Its CEO is Richard M. Weil.

For a complete fundamental analysis analysis of Janus Capital Group Inc, check out Equities.com’s Stock Valuation Analysis report for JNS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.